Clinical Application of AMPs
Antimicrobial peptides (AMPs) have been described as one of the most promising compounds able to address one of the main health threats of the twenty-first century that is the continuous rise of multidrug-resistant microorganisms. However, despite the clear advantages of AMPs as a new class of antimicrobials, such as broad spectrum of activity, high selectivity, low toxicity and low propensity to induce resistance, only a small fraction of AMPs reported thus far have been able to successfully complete all phases of clinical trials and become accessible to patients. This is mainly related to the low bioavailability and still somewhat expensive production of AMP along with regulatory obstacles. This chapter offers an overview of selected AMPs that are currently in the market or under clinical trials. Strategies for assisting AMP industrial translation and major regulatory difficulties associated with AMP approval for clinical evaluation will be also discussed.
- Cardoso MH, Cândido ES, Oshiro KGN, Rezende SB, Franco OL (2018) Peptides containing D-amino acids and retro-inverso peptides: general applications and special focus on antimicrobial peptides. In: Koutsopoulos S (ed) Peptide applications in biomedicine, biotechnology and bioengineering. Woodhead Publishing, Elsevier Ltd, Kidlington, pp 131–155CrossRefGoogle Scholar
- ClinicalTrials.gov (n.d.) https://www.clinicaltrials.gov/
- ClinicalTrialsPage (n.d.) https://www.nia.nih.gov/health/what-are-clinical-trials-and-studies. Accessed Jul 2018.
- Collins JJ, Koeris M, Lu TKT, et al. (2015) Bacteriophages expressing antimicrobial peptides and uses thereof. US 2015/0050717 A1Google Scholar
- DrugDataBase (n.d.) http://www.drugsdb.eu/index.php?l=c. Accessed Jul 2018.
- Eckert RH, Yarbrough D, Shi W, et al (2014) Selectively targeted antimicrobial peptides and the use thereof. EP2801368A1 2014Google Scholar
- Giuliani A, Pirri G, Nicoletto SF (2007) Antimicrobial peptides: an overview of a promising class of therapeutics. Cent Eur J Biol 2(1):1–33Google Scholar
- Hoffmann R, Berthold N, Nollmann F (2014). Modified antibiotic peptides having variable systemic release. US20140309161 A1. 2014Google Scholar
- Molchanova N, Hansen PR, Franzyk H (2017) Advances in development of antimicrobial peptidomimetics as potential drugs. Molecules 22(9):1–60Google Scholar
- Morris CJ, Beck K, Fox MA, Ulaeto D, Clark GC, Gumbleton M (2012) Pegylation of antimicrobial peptides maintains the active peptide conformation, model membrane interactions, and antimicrobial activity while improving lung tissue biocompatibility following airway delivery. Antimicrob Agents Chemother 56(6):3298–3308CrossRefPubMedPubMedCentralGoogle Scholar
- Mygind PH, Fischer RL, Schnorr KM, Hansen MT, Sonksen CP, Ludvigsen S, Raventos D, Buskov S, Christensen B, De Maria L, Taboureau O, Yaver D, Elvig-Jorgensen SG, Sorensen MV, Christensen BE, Kjaerulff S, Frimodt-Moller N, Lehrer RI, Zasloff M, Kristensen HH (2005) Plectasin is a peptide antibiotic with therapeutic potential from a saprophytic fungus. Nature 437(7061):975–980CrossRefPubMedGoogle Scholar
- Otvos L, Wade JD (2014) Current challenges in peptide-based drug discovery. Front Chem 2:1–4Google Scholar
- Rai A, Pinto S, Velho TR, Ferreira AF, Moita C, Trivedi U, Evangelista M, Comune M, Rumbaugh KP, Simoes PN, Moita L, Ferreira L (2016b) One-step synthesis of high-density peptide-conjugated gold nanoparticles with antimicrobial efficacy in a systemic infection model. Biomaterials 85:99–110CrossRefPubMedGoogle Scholar
- Sader HS, Fedler KA, Rennie RP, Stevens S, Jones RN (2004) Omiganan pentahydrochloride (MBI 226), a topical 12-amino-acid cationic peptide: spectrum of antimicrobial activity and measurements of bactericidal activity. Antimicrob Agents Chemother 48(8):3112–3118CrossRefPubMedPubMedCentralGoogle Scholar
- Scott A (2018) Peptide makers face threat from biotechnology how a 1-year-old German start-up could be about to shake up a $1 billion market. Chem Eng News 96(5):4–4Google Scholar
- Silva T, Magalhaes B, Maia S, Gomes P, Nazmi K, Bolscher JGM, Rodrigues PN, Bastos M, Gomes MS (2014) Killing of mycobacterium avium by lactoferricin peptides: improved activity of arginine- and D-amino-acid-containing molecules. Antimicrob Agents Chemother 58(6):3461–3467CrossRefPubMedPubMedCentralGoogle Scholar
- Vidal L, Geffard M (2014) Lauryl-poly-L-lysine: a new antimicrobial agent? FEBS J 281:328–328Google Scholar
- WebPage, P (n.d.) http://www.polyphor.com/pol7080/. Accessed Jul 2018.
- Willcox MDP, Kumar N, Cole N, et al. (2013) Antimicrobial peptides and uses thereof. WO2013076666 A1. 2013Google Scholar
- WIPO (2018) https://patentscope.wipo.int/search/pt/search.jsf.